Tiziana Life Sciences Doses First Patient in Phase 2 Trial for Intranasal Foralumab in Early Alzheimer's Disease
Summary
Tiziana Life Sciences Ltd. (TLSA) announced the dosing of the first patient in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab for early Alzheimer’s disease (AD). The trial will assess the fully human anti-CD3 monoclonal antibody both as a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab. This move is supported by new TSPO-PET imaging evidence indicating persistent microglial activation and neuroinflammation in AD patients even after amyloid plaque reduction, positioning foralumab to address this critical inflammatory component.
Tiziana Life Sciences dosed the first patient in its Phase 2 trial for intranasal foralumab in early Alzheimer's disease. The trial combines the drug with anti-amyloid therapies like lecanemab and donanemab. This addresses persistent neuroinflammation observed after amyloid plaque reduction.
Key Takeaways
- Phase 2 trial initiation evaluates intranasal foralumab in early Alzheimer’s disease.
- The study tests monotherapy and combination use with FDA-approved anti-amyloid drugs.
- TSPO-PET imaging confirms neuroinflammation persists despite existing amyloid clearance treatments.
Sentiment: Neutral
Trial commencement is a positive milestone, but efficacy data is still pending from this mid-stage study.
Disclaimer: This is an AI-generated summary of a press release . The model used to summarize this release may make mistakes. See the full release here.
